Literature DB >> 7512589

How many specific B cells are needed to protect against a virus?

M F Bachmann1, T M Kündig, C P Kalberer, H Hengartner, R M Zinkernagel.   

Abstract

The size of the Ab repertoire has been estimated to comprise theoretically somewhere between > 10(10) and approximately 10(4) specificities, dependent on the criteria used. In an attempt to estimate the anti-viral protective Ab repertoire of the mouse the B cell and Ab-forming cell (AFC) frequencies and protective neutralizing Ab levels during the course of an infection with vesicular stomatitis virus (VSV) were analyzed. Determination of AFC frequencies, limiting dilution assays, and adoptive transfer experiments to SCID mice revealed that during the acute phase (day 8) of the immune response, more than 50% of all IgG2a-producing AFCs were specific for VSV, most of them recognizing the neutralizing determinant. In a later phase (days 21 or 50), 10 to 20 times fewer VSV-specific AFCs were present, corresponding to a frequency of approximately 1:10(4) spleen cells. Finally, in a protection assay in SCID mice, adoptively transferred protective Ab concentrations were found to be approximately 1 to 10 micrograms Ab/ml mouse serum. Because during the memory phase of the anti-VSV response usually 10(4) AFC/mouse are engaged to maintain a high level of memory IgG against the neutralizing determinant on VSV and if one assumes a total number of about 10(6) AFCs/mouse, these data suggest a rather limited neutralizing anti-viral protective memory-AFC repertoire of 10(2) to 10(4) different specificities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7512589

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Immunological memory ≠ protective immunity.

Authors:  Rolf M Zinkernagel
Journal:  Cell Mol Life Sci       Date:  2012-04-06       Impact factor: 9.261

2.  Spatially addressed combinatorial protein libraries for recombinant antibody discovery and optimization.

Authors:  Hongyuan Mao; James J Graziano; Tyson M A Chase; Cornelia A Bentley; Omar A Bazirgan; Neil P Reddy; Byeong Doo Song; Vaughn V Smider
Journal:  Nat Biotechnol       Date:  2010-10-24       Impact factor: 54.908

3.  Antiviral immune responses in Itk-deficient mice.

Authors:  M F Bachmann; D R Littman; X C Liao
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 4.  The role of germinal centers for antiviral B cell responses.

Authors:  M F Bachmann
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

5.  Immunogenicity of protein therapeutics: The key causes, consequences and challenges.

Authors:  Matthew P Baker; Helen M Reynolds; Brooke Lumicisi; Christine J Bryson
Journal:  Self Nonself       Date:  2010-10

6.  Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.

Authors:  H P Roost; M F Bachmann; A Haag; U Kalinke; V Pliska; H Hengartner; R M Zinkernagel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

7.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1.

Authors:  J P Moore; Y Cao; D D Ho; R A Koup
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  A Single Locus Controls Interferon Gamma-Independent Antiretroviral Neutralizing Antibody Responses.

Authors:  Melissa Kane; Felicity Deiss; Alexander Chervonsky; Tatyana V Golovkina
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

9.  Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction.

Authors:  M F Bachmann; H Hengartner; R M Zinkernagel
Journal:  Med Microbiol Immunol       Date:  1994-12       Impact factor: 3.402

10.  Bone marrow is a major site of long-term antibody production after acute viral infection.

Authors:  M K Slifka; M Matloubian; R Ahmed
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.